REGN stock forecast, quote, news & analysis

Key Takeaways

• Regeneron Pharmaceuticals (REGN) has climbed roughly 28% over the last 30 days, rising from about $651 to approximately $834 per share.
• The move was driven primarily by a strong second-quarter 2026 earnings report, released on July 30, that beat analyst expectations on both revenue and earnings.
• Record quarterly sales from Dupixent, EYLEA HD, and Libtayo, along with the full repayment of the Sanofi development balance, powered investor optimism.
• Over the last quarter, the stock has gained approximately 30%, with nearly all of that advance concentrated in the weeks following the earnings release.
• Near-term catalysts include a November FDA decision on cemdisiran and multiple late-stage pipeline readouts expected later in 2026.

Regeneron Pharmaceuticals (REGN) Company Overview and Market Position

Regeneron Pharmaceuticals is a Tarrytown, New York-based biotechnology company that discovers, develops, and commercializes medicines for serious diseases. The company is best known for its blockbuster immunology and eye-disease franchises. Dupixent (dupilumab), developed and commercialized in collaboration with Sanofi (SNY), is one of the world's leading therapies for atopic dermatitis, asthma, and a growing list of inflammatory conditions. EYLEA and its higher-dose successor EYLEA HD (aflibercept), co-developed with Bayer (BAYRY), anchor its ophthalmology portfolio, while Libtayo (cemiplimab) is the foundation of its oncology franchise.

Regeneron's competitive strength lies in its proprietary antibody-discovery technologies and a deep pipeline of roughly 50 clinical programs spanning immunology, oncology, ophthalmology, and genetic medicines. With a net cash position of more than $15 billion, the company also maintains meaningful financial flexibility. Investors follow the stock closely because of its diversified revenue base, recurring pipeline milestones, and long-standing partnerships with Sanofi and Bayer.

Regeneron Pharmaceuticals (REGN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, REGN shares have advanced roughly 28%, rising from a closing price of approximately $651 to about $834. This sharp move lifted the stock to a new 52-week high, breaking above its prior high of $821.11.

The last-quarter picture tells a similar but more concentrated story. Three months earlier, near the end of May, the stock traded around $639, implying a gain of roughly 30% over the full period. Notably, the stock was largely range-bound through May, June, and much of July — it closed near $650 on both May 20 and July 22, with a dip to a low around $615 in late May — before breaking out decisively after the second-quarter earnings report. In other words, the overwhelming majority of the quarterly advance occurred in the final three weeks of the period.

What Drove REGN Stock Price in the Last 30 Days

The primary catalyst behind the 30-day surge was Regeneron's second-quarter 2026 financial results, reported on July 30. The company posted revenue of $4.29 billion, up 17% year over year and ahead of the roughly $3.82 billion consensus estimate, while non-GAAP diluted earnings per share of $14.29 beat the approximately $10.16 analyst consensus by a wide margin.

Several underlying factors supported the beat. Dupixent generated $6.0 billion in global net sales (recorded by Sanofi), up 38% year over year on a constant-currency basis. EYLEA HD U.S. net sales rose 52% to $596 million, and for the first time exceeded legacy EYLEA sales, now representing roughly 60% of the U.S. franchise. Libtayo global sales climbed 29% to $489 million. Collaboration revenue from Sanofi reached an all-time high of $2.2 billion, up 51%.

A particularly important financial development was Regeneron's full repayment of the Sanofi development balance, which the company said should drive a meaningful step-up in collaboration revenue beginning in the third quarter. Management's guidance commentary, combined with commentary from analysts noting that second-half results should look stronger, reinforced the positive sentiment that propelled the rally.

What Drove REGN Stock Performance Over the Last Quarter

The broader quarterly trend reflects a gradual repositioning of Regeneron's product portfolio. Through much of the period, investors weighed the ongoing decline of legacy EYLEA — down 45% year over year in the second quarter amid competition from Roche's (RHHBY) Vabysmo and biosimilar pressure — against the rapid ramp of EYLEA HD and Dupixent's continued expansion into new indications.

Several label expansions earlier in 2026 laid the groundwork for the eventual breakout. In April, the FDA and European Commission approved Dupixent for chronic spontaneous urticaria in children aged 2–11, and the FDA approved extended EYLEA HD dosing intervals of up to every 20 weeks. These regulatory wins, together with the second-quarter earnings beat, shifted investor focus toward the company's growth franchises and away from the mature EYLEA erosion. The quarterly advance therefore reflects both improving fundamentals and a favorable reassessment of Regeneron's growth trajectory.

Trending AI Robots

For traders seeking a data-driven complement to manual analysis, Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots appear in this dedicated section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term momentum to longer-horizon trend following. Reviewing the Trending AI Robots page can help traders identify automated strategies currently drawing attention across the market.

REGN Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors are likely to shape REGN's trajectory. The most prominent near-term catalyst is an FDA decision on cemdisiran for generalized myasthenia gravis, expected in November 2026, alongside an anticipated FDA decision on garetosmab for fibrodysplasia ossificans progressiva. Investors are also watching fourth-quarter data readouts from the complement programs in paroxysmal nocturnal hemoglobinuria and geographic atrophy, as well as the initiation of Phase III studies in the company's obesity portfolio.

On the commercial front, the durability of Dupixent and EYLEA HD growth, the timing of the EYLEA HD pre-filled syringe approval, and the ongoing decline of legacy EYLEA in the face of biosimilar competition will be key. The evolving Sanofi collaboration and the company's capital-allocation approach — including share repurchases and the $0.94 quarterly dividend — also remain in focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations